Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Margaret Salfi"'
Publikováno v:
The Journal of Clinical Pharmacology. 48:1025-1031
A phase I study was conducted to evaluate the effects of renal function on the pharmacokinetics and pharmacodynamics (absolute neutrophil count [ANC]) of pegfilgrastim in nonneutropenic subjects. Thirty subjects categorized into 5 renal function grou
Publikováno v:
Clinical Drug Investigation. 28:635-643
The calcimimetic cinacalcet lowers blood para-thyroid hormone (PTH), calcium and phosphorus levels and calcium-phosphorus product in patients with chronic kidney disease receiving dialysis. Cinacalcet is metabolized primarily through oxidative and co
Autor:
Margaret Salfi, Tsui Chern Cheah, Alessandra Cesano, David D. Hurd, Parnian Zia-Amirhosseini, Jeffrey Aycock
Publikováno v:
Pharmacotherapy. 27:1353-1360
Study Objective. To assess the pharmacokinetic profile of palifermin after intravenous dosing with either a collapsed dose of 180 μg/kg/day for 1 day or a standard dose of 60 μg/kg/day for 3 days, before and after myeloablative chemoradiotherapy an
Publikováno v:
The Journal of Clinical Pharmacology. 46:654-661
The objective of this study was to compare the pharmacokinetics of liquid and reconstituted lyophilized etanercept. This single-center, open-label study had a 2-period crossover design in which 36 healthy subjects were randomly assigned in a 1:1 rati
Autor:
Wayne Yates, Philip Leese, John T. Sullivan, Margaret Salfi, Dimitry M. Danilenko, Brian D. Ring, Parnian Zia-Amirhosseini, Alessandra Cesano
Publikováno v:
Clinical Pharmacology & Therapeutics. 79:558-569
Background Palifermin is a recombinant human keratinocyte growth factor approved to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies who received myelotoxic therapy requiring hematopoietic stem ce
Publikováno v:
European Journal of Clinical Pharmacology. 63:159-163
In vitro work has demonstrated that cinacalcet is a strong inhibitor of cytochrome P450 isoenzyme (CYP) 2D6. The purpose of this study was to evaluate the effect of cinacalcet on CYP2D6 activity, using desipramine as a probe substrate, in healthy sub
Publikováno v:
Clinical Pharmacokinetics. 44:509-516
Cinacalcet (cinacalcet HCl; Sensipar®/Mimpara®) is a calcimimetic that is a treatment for secondary hyperparathyroidism in patients with renal failure. The objective of this study was to assess the effects of renal function and dialysis on the phar
Autor:
Thomas Marbury, John T. Sullivan, Desmond Padhi, Robert Z Harris, Robert J. Noveck, Margaret Salfi
Publikováno v:
American Journal of Kidney Diseases. 44:1070-1076
Background: Cinacalcet hydrochloride (HCl) can be used to manage the secondary hyperparathyroidism of patients with chronic kidney disease. This study investigated the pharmacokinetics, pharmacodynamics, safety, and tolerability of cinacalcet HCl ove
Publikováno v:
British Journal of Clinical Pharmacology. 50:581-589
Aims To evaluate whether ketoconazole or cimetidine alter the pharmacokinetics of loratadine, or its major metabolite, desloratadine (DCL), or alter the effects of loratadine or DCL on electrocardiographic repolarization in healthy adult volunteers.
Autor:
Demetris N. Zambas, Margaret Salfi, Samir K. Gupta, Steven Schenker, Robert P. Clement, Paul Glue
Publikováno v:
British Journal of Clinical Pharmacology. 49:417-421
Aims The primary objective of this study was to describe the single dose pharmacokinetics of ribavirin in subjects with normal liver function and those with various degrees of stable chronic liver disease. Additionally this study assessed the safety